3) Chemoresistance
[,keməri'zistəns]
化疗耐药
1.
Mutation, translocation and loss of some genes have been known to contribute to chemoresistance, epigenetic mechanisms may also play an important role.
表观遗传(eprgenetic)和基因突变、易位、缺失等事件同样在化疗耐药的形成中有重要的作用。
2.
In order to study the relationship between the expression of glutathione S transferase(GST) in leukemic cells and the chemoresistance in patients with acute leukemia, the expressions of GST activity and GST mRNA were measured according to spectrophotometric assay based on the use of 1 choloro 2, 4 dinitro benzene and in situ hybridization.
为了探讨白血病细胞内谷胱甘肽硫转移酶 (GST)的表达与化疗耐药的关系 ,本研究采用 1 氯 2 ,4 二甲基为底物的比色分析法和原位杂交法对 5 6例白血病患者白血病细胞内GST的表达进行检测 ,并结合临床化疗药物敏感度和治疗效果进行临床分析。
3.
Objective To investigate the impacts of cytotoxic drugs on APE/ref-1 expression in A549 cell, in order to find the potential relationship between APE/ref-1 and chemoresistance of NSCLC.
结论 APE/ref-1表达增强及其在细胞内不同部位表达强度的变化可能和NSCLC对化疗耐药性的产生相关。
4) Drug resistance
化疗耐药
1.
Study on drug resistance in pediatric leukemia;
儿童急性淋巴细胞白血病细胞化疗耐药机制的探讨
5) chemoresistance
[,keməri'zistəns]
化疗耐药性
1.
Activity of PI3 K/Akt/FKHRL1 signaling pathway induced by Doxorubicin confer chemoresistance in gastric cancer cell;
阿霉素诱导PI3’K/Akt/FKHRL1通路激活与胃癌细胞化疗耐药性的关系
2.
【Objectives】 To investigate the changes of CN-Ⅱand APE / Ref-1 expression in human lung cancer cell line A549 after induction of gemcitabine and to study the effects of gemcitabine on chemoresistance in lung cancer.
【结论】CN-Ⅱ和APE/Ref-1在肺癌化疗时表达明显增强,可能与化疗耐药性的产生有关,并提示针对CN-Ⅱ和APE/Ref-1的靶向干预可能有助于提高肺癌的化疗敏感性。
6) chemotherapy resistance
化疗耐药性
1.
To investigate the relationship between the expression of NFkB family proteins, P53 and MDM2 in ovarian cancer cell lines and chemotherapy resistance of ovarian cell lines, 13 ovarian cancer cell lines were cultured, and then protein was extracted separately from cytoplasm, nuclear or total cells.
培养13个卵巢癌细胞系,提取癌细胞蛋白,采用Western印迹法观察NFkB家族蛋白、P53和MDM2的表达,并用四氮唑盐法药敏试验观察与卵巢癌细胞化疗耐药性关系。
补充资料：卵巢癌单一药物化疗
卵巢癌单一药物化疗
卵巢上皮癌的单一药物化疗，仅用一种药物进行化疗。由于其效果不如联合化疗，故目前已较少采用。但因其用法简单，宜于较长时间在门诊治疗，故多用于早期病例术后的巩固治疗，或用于因其他并发症，无法耐受联合化疗者。常用药物①马利兰(Melphalan)0.2mg/(kg·d)，5天为1个疗程，间隔3～4周；②塞替派(Thiotepa)20mg加生理盐水20ml，静推，隔日1次，共8次，总量160mg；或40mg＋生理盐水300ml，腹腔注射，每周2次，总量200mg，均间隔4周；③六甲嘧胺(hexamethylmelamine,HMM)200～250mg/m2，连续2周，或8mg/kg·d，连服3个月，间隔4周。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条